- Home
- EVN vs FDMT Comparison
EVN vs FDMT Comparison
Compare EVN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | FDMT |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 476.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EVN | FDMT |
|---|---|---|
| Price | $11.03 | $9.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $34.13 |
| AVG Volume (30 Days) | 101.2K | ★ 728.1K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $8.64 | $2.24 |
| 52 Week High | $10.45 | $12.34 |
Technical Indicators
Market Signals| Indicator | EVN | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 59.94 |
| Support Level | $10.95 | $8.75 |
| Resistance Level | $11.10 | $9.78 |
| Average True Range (ATR) | 0.10 | 0.63 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 89.13 | 83.00 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.